Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Pegfilgrastim

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44337   clinical trials with a EudraCT protocol, of which   7367   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    79 result(s) found for: Pegfilgrastim. Displaying page 1 of 4.
    1  2  3  4  Next»
    EudraCT Number: 2006-001409-27 Sponsor Protocol Number: ONC-2006-001 Start Date*: 2006-06-29
    Sponsor Name:ISTITUTO CLINICO HUMANITAS
    Full Title: Pegfilgrastim versus filgrastim after high-dose chemotherapy followed by autologous peripheral blood stem cell, in patients with hematologic and solid tumors a randomized phase II study
    Medical condition: Patients with hematological neoplasia or solid tumors treated with high-dose chemotherapy
    Disease: Version SOC Term Classification Code Term Level
    6.1 10027655 HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-001005-26 Sponsor Protocol Number: GECP 05-01 Start Date*: 2005-09-07
    Sponsor Name:Spanish Lung Cancer Group
    Full Title: A single-arm phase II study of dose-dense gemcitabine and carboplatin as neoadyuvant chemotherapy, with pegfilgrastim support for subjects with operable stage IIIA NSCLC
    Medical condition: Non-small cell lung cancer
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: View results
    EudraCT Number: 2006-000891-34 Sponsor Protocol Number: ERA2006001 Start Date*: 2006-05-05
    Sponsor Name:Hôpital Ambroise Paré
    Full Title: A randomized, international, open-label, phase II study of peripheral blood progenitor cell (PBPC) mobilization and engraftment with pegfilgrastim or filgrastim for autologous transplantation in su...
    Medical condition: Multiple Myeloma .
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-004321-95 Sponsor Protocol Number: AMLSG 07-04 Start Date*: 2005-05-26
    Sponsor Name:University of Ulm
    Full Title: RANDOMIZED PHASE II-STUDY ON VALPROIC ACID, ALL-TRANS RETINOIC ACID AND THEIR COMBINATION IN INDUCTION AND CONSOLIDATION THERAPY AS WELL AS PEGFILGRASTIM AFTER CONSOLIDATION THERAPY IN YOUNGER PATI...
    Medical condition: newly diagnosed acute myeloid leukemia
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2016-003469-24 Sponsor Protocol Number: SPI-GCF-302 Start Date*: 2017-03-14
    Sponsor Name:Spectrum Pharmaceuticals, Inc.
    Full Title: Randomized, OpEn-Label, Active-ContrOl Trial of SPI-2012 (Eflapegrastim) Versus Pegfilgrastim in the Management of Chemotherapy-Induced Neutropenia in Early-Stage BReast Cancer Patients Receiving D...
    Medical condition: Management of Neutropenia in Patients with Breast Cancer who receiving Chemotherapy with the Docetaxel + Cyclophosphamide
    Disease: Version SOC Term Classification Code Term Level
    20.0 10005329 - Blood and lymphatic system disorders 10029354 Neutropenia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: View results
    EudraCT Number: 2015-000266-64 Sponsor Protocol Number: PEGF/USV/P3/003 Start Date*: 2015-06-18
    Sponsor Name:USV Limited
    Full Title: A Randomised, Multi-Centre, Assessor-Blinded, Active-Controlled, Parallel Group, Equivalence Phase III Study Comparing the Safety and Efficacy of USV Pegfilgrastim and Neulasta® in Breast Cancer Pa...
    Medical condition: Duration of Sever Neutropenia and incidence of febrile neutropenia
    Disease: Version SOC Term Classification Code Term Level
    18.0 10005329 - Blood and lymphatic system disorders 10029354 Neutropenia PT
    18.0 10005329 - Blood and lymphatic system disorders 10016288 Febrile neutropenia PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: HU (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2017-002069-22 Sponsor Protocol Number: ET17-057 Start Date*: 2018-04-18
    Sponsor Name:CENTRE LEON BERARD
    Full Title: BREASTIMMUNE02 - A multicenter, randomized, open-label, Phase II trial aiming to evaluate the impact of pegfilgrastim on trastuzumab anti-tumor effect and antibody-dependent cell-mediated cytotoxic...
    Medical condition: Operable HER2 positive breast cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10006188 Breast cancer female NOS LLT
    Population Age: Adults Gender: Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2009-011899-30 Sponsor Protocol Number: 20080259 Start Date*: 2009-12-18
    Sponsor Name:Amgen Inc
    Full Title: A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Pegfilgrastim Administered to Subjects With Newly Diagnosed, Locally-advanced or Metastatic Colorectal Cancer Treated With Bevacizum...
    Medical condition: Locally-advanced or Metastatic Colorectal Cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10052362 Metastatic colorectal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Completed) HU (Completed) CZ (Completed) BE (Completed) IE (Completed) IT (Completed) FR (Completed) SK (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2007-006069-34 Sponsor Protocol Number: 1564 Start Date*: Information not available in EudraCT
    Sponsor Name:POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI
    Full Title: Clinical efficacy and cell mobilization activity of pegfilgrastim in patients with gynaecological malignancies in therapy with topotecan.
    Medical condition: ovarian cancer, cervical cancer, endometrial cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10038594 Reproductive neoplasms female malignant and unspecified HLGT
    Population Age: Adults Gender: Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2013-001284-23 Sponsor Protocol Number: XM22-ONC-305 Start Date*: 2013-12-10
    Sponsor Name:Merckle GmbH
    Full Title: A randomized, phase IIIB, open-label, two-arm, multicenter, comparatiVe study on efficacy and safety of lipegfilgrastim (Lonquex, TEVA) in comparison to pegfilgrastim (Neulasta®, Amgen) in elderly ...
    Medical condition: The study population includes patients with aggressive B cell Non-Hodgkin Lymphoma (NHL) planned to receive systemic anti-cancer therapy with at least 6 cycles of R-CHOP-21, according to local stan...
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004864 10066481 Hematological malignancy LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-004792-14 Sponsor Protocol Number: 0298-21 Start Date*: 2021-09-08
    Sponsor Name:Intas Pharmaceuticals Ltd.
    Full Title: A Randomized, Active-Controlled, Multicenter, Open label, Two Arm Study to Assess Safety, Efficacy, Pharmacodynamics, and Pharmacokinetics with Pegfilgrastim PFS of Intas Pharmaceutical Limited Com...
    Medical condition: Paediatric Patients Under 6 years of Age with Rhabdomyosarcoma or Wilms’ Tumour on Myelosuppressive Chemotherapy (CmT) Regimen
    Disease: Version SOC Term Classification Code Term Level
    20.0 10005329 - Blood and lymphatic system disorders 10047954 White blood cell disorders HLGT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: (No results available)
    EudraCT Number: 2015-002693-20 Sponsor Protocol Number: GX‐G3_NHL_2/CGX14001 Start Date*: 2016-01-21
    Sponsor Name:Ilkogen Ilac San. ve Tic. A.S.
    Full Title: A randomized, parallel group, multi-centre phase-2 study of GX-G3 compared with pegfilgrastim as an adjunct to chemotherapy in patients with Non-Hodgkin’s Lymphoma
    Medical condition: Neutropenia
    Disease: Version SOC Term Classification Code Term Level
    20.0 10005329 - Blood and lymphatic system disorders 10029354 Neutropenia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Completed)
    Trial results: View results
    EudraCT Number: 2006-001963-52 Sponsor Protocol Number: GAMEC II Start Date*: 2006-07-03
    Sponsor Name:Queen Mary University London
    Full Title: GAMEC-SHORT (S) & GAMEC-ANTHRACYCLINE (A) RISK-ADAPTED PROTOCOL FOR RELAPSED GERM CELL TUMOURS (GCT)
    Medical condition: Open-labelled, non-randomised clinical trial in patients with relapsed germ cell tumours (GCT.)
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-002971-42 Sponsor Protocol Number: PEG-HSR Start Date*: 2006-06-19
    Sponsor Name:OSPEDALE S. RAFFAELE
    Full Title: Outpatients high-dose chemotherapy supported by autologus peripheral blood stem and single-dose pegfilgrastim in patients with lymphoproliferative malignances.
    Medical condition: patients affected by linphoproliferative pathologies
    Disease: Version SOC Term Classification Code Term Level
    9.1 10005329 Blood and lymphatic system disorders SOC
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-006541-14 Sponsor Protocol Number: ema3_pegAML Start Date*: 2007-07-27
    Sponsor Name:AZIENDA OSPEDALIERA SPEDALI CIVILI DI BRESCIA
    Full Title: A phase II pilot trial to evaluate the efficacy of treatment with Pegilate G-CSF in a group of elderly patients AML without chemotherapy indications
    Medical condition: acute mieloid leukemia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10000880 Acute myeloid leukaemia LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2008-000103-29 Sponsor Protocol Number: MM-PEG-08 Start Date*: 2008-02-21
    Sponsor Name:OSPEDALE POLICLINICO S. MATTEO
    Full Title: A single arm phase 2 study on the efficacy of Pegfilgrastim (Neulasta) after DCEP chemotherapy: a feasibility study in multiple myeloma patients eligible for autologous transplant.
    Medical condition: multiple myeloma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-002136-10 Sponsor Protocol Number: GRIFO-A Start Date*: 2005-07-08
    Sponsor Name:ISTITUTO GIANNINA GASLINI
    Full Title: Comparison between once-per-cycle peg-Filgrastim and daily injection r-Hu-G-CSF in chemotherapy-induced neutropenia treatment and peripheral blood progenitor cells mobilization in childhood.
    Medical condition: chemotherapy-induced neutropenia treatment peripheral blood progenitor cells mobilization
    Disease: Version SOC Term Classification Code Term Level
    6.1 10029354 PT
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-002039-28 Sponsor Protocol Number: LA-EP06-302 Start Date*: 2012-09-14
    Sponsor Name:Sandoz GmbH
    Full Title: Pivotal study in breast cancer patients investigating efficacy and safety of LA-EP2006 and Neulasta®
    Medical condition: Breast Cancer
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2009-015999-10 Sponsor Protocol Number: XM22-03 Start Date*: 2010-03-02
    Sponsor Name:BioGeneriX AG
    Full Title: Efficacy and Safety of XM22 compared to pegfilgrastim in patients with breast cancer receiving chemotherapy. A multinational, multicentre, randomised, double-blind controlled study
    Medical condition: Breast cancer high risk stage II, III or IV according to AJCC classification
    Disease: Version SOC Term Classification Code Term Level
    12.0 10006200 Breast cancer stage II PT
    12.0 10006201 Breast cancer stage III PT
    12.0 10006202 Breast cancer stage IV PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Completed)
    Trial results: View results
    EudraCT Number: 2016-004539-18 Sponsor Protocol Number: PGCN-001 Start Date*: 2018-08-27
    Sponsor Name:Prolong Pharmaceuticals, LLC
    Full Title: A Phase 2, Open-Label, Multicenter, Efficacy, Safety, Tolerability, and Pharmacokinetic Study of ANF–Rho™ in Patients with Chronic Neutropenia
    Medical condition: Chronic neutropenia
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000013471 10066702 Chronic neutropenia LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed May 21 23:22:56 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA